Drug Trial Radar · NCT00065962
Secretin for the Treatment of Autism
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Jun 1999
Primary completion
Not stated
Study completion May 2000
Sponsor
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
- Sponsor type
- NIH
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- First posted
- Aug 5, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
Conditions
- Autism
Interventions
secretin, synthetic porcineDrug
secretin, biologically derived porcineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital
Denver, Colorado
Center on Human Development and Disability
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.